What is Faks?
Founded in 2020, Faks operates a specialized B2B platform designed to bridge the communication gap within the pharmaceutical sector. The company provides a secure, modular, and neutral digital environment that facilitates essential business processes, including the management of expired medications, complex claims processing, and the execution of trade campaigns. With a robust network comprising over 17,000 pharmacies and 500 laboratories, Faks has effectively digitized legacy workflows that previously relied on fragmented, manual communication channels. Its market position is defined by its ability to provide a unified interface that enhances collaboration and transparency across the entire pharmaceutical ecosystem, positioning the firm as a cornerstone of digital transformation in the French healthcare market.
How much funding has Faks raised?
Faks has raised a total of $11.6M across 2 funding rounds:
Other Financing Round
$5.4M
Other Financing Round
$6.2M
Other Financing Round (2023): $5.4M with participation from Cocoa Ventures, Seedcamp, and Connect Ventures
Other Financing Round (2025): $6.2M led by Seedcamp, Speedinvest, Connect Ventures, and FJ Labs
Key Investors in Faks
Seedcamp
Seedcamp is a venture capital firm that supports early-stage startups by providing investment, mentorship, and access to a global network. The firm focuses on ambitious founders and innovative companies across various sectors, helping them grow from initial concepts to successful businesses.
Speedinvest
Speedinvest is a venture capital fund with over 1 billion euros allocated for investing in pre-Seed, Seed, and early-stage tech startups across Europe, focusing on sectors including SaaS infrastructure and Health Bio.
FJ Labs
FJ Labs specializes in angel investing at a venture scale, focusing on marketplaces and network effect businesses, with a portfolio that includes numerous unicorn-status companies.
What's next for Faks?
With this latest capital infusion, Faks is well-positioned to accelerate its enterprise-level scaling strategy. The company is expected to leverage these resources to deepen its product integration, potentially expanding its modular service offerings to address broader supply chain challenges. As the firm transitions from a high-growth startup to a more mature enterprise player, the focus will likely shift toward increasing market penetration across Europe and enhancing the platform's data-driven insights for its growing user base. By maintaining its neutral stance and commitment to secure, efficient communication, Faks is poised to further solidify its role as an indispensable partner for pharmacy groups and laboratories seeking to optimize their operational performance in an increasingly digitized industry.
See full Faks company page
